Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on June 8, 2023. The filing discloses interim clinical data from the Phase 1/2 dose escalation and expansion trial of ARV-766, an investigational orally bioavailable PROTAC protein degrader designed to treat metastatic castration-resistant prostate cancer (mCRPC). The data cutoff date for the reported results was April 2023.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial progress and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details significant clinical activity for ARV-766 in a heavily pre-treated patient population:
- Patient Profile: 100% of patients had prior treatment with novel hormonal agents (NHAs). The median number of prior therapy lines was 4 in Phase 1 and 5 in Phase 2.
- Efficacy in Mutated Populations: Among patients with AR ligand binding domain (LBD) mutations (28% of the cohort), 42% achieved a PSA reduction of ≥50% (PSA50). Specifically, 3 of 5 patients with L702H mutations and 3 of 3 patients with co-occurring T878/H875/L702 mutations achieved PSA50.
- Tumor Response: Of four evaluable patients with AR LBD mutations, one achieved a confirmed partial response and one achieved an unconfirmed partial response.
- Safety and Tolerability: ARV-766 was well-tolerated with no Grade ≥4 treatment-related adverse events (TRAEs). No dose-limiting toxicities were observed in Phase 1. The most frequent TRAEs (>10%) in Phase 1 were fatigue, nausea, and diarrhea. Only one patient in Phase 2 discontinued due to a TRAE.
- Dose Selection: Based on pharmacokinetics and tolerability, 100 mg and 300 mg once daily were selected as recommended Phase 2 expansion doses.
Guidance, Outlook, and Risks
Management outlined anticipated milestones for its AR franchise (bavdegalutamide and ARV-766) for the second half of 2023:
- Submission and presentation of updated data, including radiographic progression-free survival, for bavdegalutamide at a medical congress.
- Initiation of a global Phase 3 trial with bavdegalutamide in mCRPC.
- Completion of enrollment in the Phase 1b combination study of bavdegalutamide plus abiraterone.
- Initiation of a Phase 1b/2 trial with ARV-766 in combination with abiraterone for patients not previously treated with NHAs.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks in clinical development, trial timelines, and regulatory approvals.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and presentation (Exhibit 99.2) for detailed statistical tables not summarized in the 8-K text.
- Confirm the enrollment status and timeline for the upcoming Phase 3 trial of bavdegalutamide.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for updates on the Phase 1b/2 combination trial of ARV-766 with abiraterone.